Literature DB >> 25110635

Multidrug-resistant tuberculosis treatment with linezolid-containing regimen.

Maham Farshidpour1, Golnaz Ebrahimi2, Mehdi Mirsaeidi3.   

Abstract

The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was treated successfully with a linezolid-containing regimen. It was found that linezolid is an efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment was maintained for 18 months, and closely monitoring toxicities did not reveal evidence of any neurologic adverse effects. However, despite our expectation, thrombocytopenia was seen after 2 years follow-up.

Entities:  

Keywords:  Linezolid; Multidrug-resistant tuberculosis; Thrombocytopenia; Treatment

Year:  2013        PMID： 25110635      PMCID： PMC4123797          DOI： 10.1016/j.ijmyco.2013.09.002

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN： 2212-5531


  19 in total

1.  Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.

Authors:  Seyed Mehdi Mirsaeidi; Payam Tabarsi; Kaveh Khoshnood; Majid Valiollah Pooramiri; Ali Rowhani-Rahbar; Seyed Davood Mansoori; Heydar Masjedi; Soheyla Zahirifard; Foroozan Mohammadi; Parisa Farnia; Mohammad Reza Masjedi; Ali Akbar Velayati
Journal:  Int J Infect Dis       Date:  2005-09-23       Impact factor: 3.623

2.  Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin.

Authors:  Michele Pinon; Carlo Scolfaro; Elisabetta Bignamini; Giorgio Cordola; Irene Esposito; Rosangela Milano; Federica Mignone; Chiara Bertaina; Pier-Angelo Tovo
Journal:  Pediatrics       Date:  2010-10-25       Impact factor: 7.124

3.  Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: introduction and diagnosis of tuberculosis in children.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2006-10       Impact factor: 2.373

4.  After 40 years, new medicine for combating TB.

Authors:  Mehdi Mirsaeidi
Journal:  Int J Mycobacteriol       Date:  2013-03

5.  Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Authors:  I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2006-07-19       Impact factor: 5.790

Review 6.  Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis.

Authors:  Umesh G Lalloo; Rishendran Naidoo; Anish Ambaram
Journal:  Curr Opin Pulm Med       Date:  2006-05       Impact factor: 3.155

7.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Authors:  G B Migliori; B Eker; M D Richardson; G Sotgiu; J-P Zellweger; A Skrahina; J Ortmann; E Girardi; H Hoffmann; G Besozzi; N Bevilacqua; D Kirsten; R Centis; C Lange
Journal:  Eur Respir J       Date:  2009-03-12       Impact factor: 16.671

9.  Linezolid in the treatment of multidrug-resistant tuberculosis.

Authors:  G F Schecter; C Scott; L True; A Raftery; J Flood; S Mase
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

10.  Intrapulmonary penetration of linezolid.

Authors:  David Honeybourne; Caroline Tobin; Gail Jevons; Jenny Andrews; Richard Wise
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790
View more
  1 in total

1.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.